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Leonam G Coutinho1, Denis Grandgirard2, Stephen L Leib2 and Lucymara F Agnez-Lima1*Abstract
Background: Bacterial meningitis is characterized by an intense inflammatory reaction contributing to neuronal
damage. The aim of this study was to obtain a comparative analysis of cytokines and chemokines in patients with
pneumococcal (PM) and meningococcal meningitis (MM) considering that a clear difference between the immune
response induced by these pathogens remains unclear.
Methods: The cyto/chemokines, IL-1β, IL-2, IL-6, TNF-α, IFN-γ, IL-10, IL-1Ra, CXCL8/IL-8, CCL2/MCP-1, CLL3/MIP-1α,
CCL4/MIP-1γ and G-CSF, were measured in cerebrospinal fluid (CSF) samples from patients with PM and MM.
Additionally, a literature review about the expression of cytokines in CSF samples of patients with MB was made.
Results: Concerning cytokines levels, only IFN-γ was significantly higher in patients with Streptococcus pneumoniae
compared to those with Neisseria meningitidis, regardless of the time when the lumbar puncture (LP) was made.
Furthermore, when samples were compared considering the timing of the LP, higher levels of TNF-α (P <0.05) were
observed in MM patients whose LP was made within 48 h from the initial symptoms of disease. We also observed
that the index of release of cyto/chemokines per cell was significantly higher in PM. From the literature review,
it was observed that TNF-α, IL-1β and IL-6 are the best studied cytokines, while reports describing the
concentration of the cytokine IL-2, IL-1Ra, G-CSF and CCL4/MIP-1β in CSF samples of patients with bacterial
meningitis were not found.
Conclusion: The data obtained in this study and the previously published data show a similar profile of cytokine
expression during PM and MM. Nevertheless, the high levels of IFN-γ and the ability to release high levels of
cytokines with a low number of cells are important factors to be considered in the pathogenesis of PM and thereby
should be further investigated. Moreover, differences in the early response induced by the pathogens were
observed. However, the differences observed are not sufficient to trigger changes in the current therapy of
corticosteroids adopted in both the PM and MM.
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Bacterial meningitis (BM) is an infectious disease charac-
terized by high mortality and morbidity rates [1]. After
Haemophilus influenza type b immunization, Streptococcus
pneumoniae and Neisseria meningitidis have become the
two main causes of BM in Brazil [2-4].
The inflammatory response plays a primordial role in
the pathogenesis of cerebral injury associated to different
meningitis etiologies [5,6]. During BM, bacterial cell-wall
components, such as lipopolysaccharide from gram-
negative bacteria and lipoteichoic acid from gram-positive
bacteria, trigger the massive release of proinflammatory
molecules. These in turn increase the permeability of the
blood–brain barrier (BBB) and attract leukocytes to the
central nervous system (CNS) (pleocytosis). Cytokines, re-
active oxygen species, reactive nitrogen species, and
matrix metalloproteinases, act in a coordinated manner to
promote an oxidative burst leading to energy failure and
cell death [7-10]. The pattern of inflammatory mediators
present in the cerebrospinal fluid (CSF) in response to an
immune assault determines the disease’s severity and its
sequelae [7,11].
BM has often been comprised in a unique group, con-
sidering that gram-positive and gram-negative bacteria
compounds trigger the same Toll-like receptors (TLR).
However, S. pneumoniae and N. meningitidis also seem
to modulate different Toll-like receptors that conse-
quently regulate a different expression of cytokines.
TLR2, TLR4, and TLR9 are important in the response
against S. pneumoniae, while TLR2 does not seem to be
essential in the host response to N. meningitidis [12-15].
Conversely, important mediators of chemoattraction,
such as CXCL8/IL-8, CCL3/MIP-1α and CCL2/MCP-1,
induce a similar intensity of response in relation to
S. pneumonia and N. meningitidis [16,17].
Although isolated studies have demonstrated higher
cytokine expression during BM caused by different
agents, they are limited in establishing differences
between the inflammatory responses induced by each
pathogen. Relevant questions, such as “are there differ-
ences between the inflammatory responses caused by
different etiologic agents of BM?” remain to be
answered. This comparative study is important because
BM continues to have a high occurrence and the out-
come from pneumococcal meningitis (PM) differs from
that of meningococcal meningitis (MM) [18,19].
Currently, the BM treatment is similar for both etio-
logical agents, i.e. antibiotics and corticosteroids. Dexa-
methasone remains as the antiinflammatory therapy
most used during BM treatment. Clinical trials have
shown reduction in unfavorable outcome, such as lower
mortality in adults and fewer neurological and auditory
sequelae in adults and children during PM, however
similar beneficial effect was not seen for dexamethasoneduring MM [20]. Thus, if there is a marked difference in
inflammatory profile, this may have implication for
immunomodulatory therapies, which should be tailored
differently for each etiology.
In this work, we measured twelve cyto/chemokines
that are commonly expressed during BM in the CSF
from patients with PM and MM and did a literature
review about reports of cyto/chemokine determination
in CSF in order to obtain further knowledge about the
inflammatory profile in BM caused by meningococci and
pneumococci. Since the inflammatory response has been
associated to the sequelae occurrence after the disease, a
better understanding of the pathophysiologic mecha-
nisms between the host and each causative agent may
contribute to designing new therapies for the reduction
of death and sequelae caused by this severe disease.
Methods
Case selection and sample collection
Twenty-eight patients who were admitted to the
Hospital Giselda Trigueiro (Natal, Brazil) with a sus-
picion of meningitis were enrolled in this study. This
study was evaluated and approved by the Committee
on Medical Ethics of the Giselda Trigueiro Hospital
and by the National Committee on Ethics (CONEP)
with number 0052.1.051.000-05. Informed consent was
obtained from each patient participating in this study.
CSF samples were collected by lumbar puncture (LP)
during standard routine for diagnosis of meningitis in
the Hospital Giselda Trigueiro. The routine diagnosis in-
cludes, evaluation of clinical symptoms, detection of the
pathogen in the CSF by Gram staining, positive bacterial
culture, number of erythrocytes, white blood cell count
(WBC) with detection of levels of polymorphonuclear
granulocytes (PMN) and protein and glucose contents.
Patients who had been treated with antibiotics before LP
or with other diseases (such as AIDS) that affect the
immune and inflammatory responses (e.g. the cytokines
expression) were not included in this study. The CSF
samples were collected from the initial LP at the time of
admission to hospital. All samples were kept at 4°C after
LP and centrifuged (3000 g, 5 min, 4°C). Supernatants
were frozen and stored at −80°C until assayed. CSF was
assigned a code for anonymization purpose and the
study was carried out according to ethical regulations.
Measurement of cyto/chemokine concentration
CSF cyto/chemokines levels were measured by a Bio-Plex
200 suspension array system (Bio-Rad, Hercules, CA,
USA) using microsphere-based multiplex assays. In the
assay, the concentration of 12 cyto/chemokines (TNF-α,
IL-6, IL-1β, IFN-γ, IL-10, IL-1Ra, CCL3/MIP-1α, CCL4/
MIP-1β, CCL2/MCP-1, G-CSF, CXCL8/IL-8 and IL-2)
was assessed in 28 CSF samples, using the human
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Research Inc., St Charles, MA, USA). This set of cyto/
chemokines was selected from literature data that report
their importance during BM in patients or in animal
models. Samples (25 μl) were measured undiluted and
in duplicate. The assay was performed according to
the manufacturer’s instructions. Samples were diluted
to fit in the dynamic range of the assay when appro-
priate. Cyto/chemokine concentrations were calculated
by Bio-Plex Manager software using a 5-parametric
logistic standard curve derived from the recombinant
cytokine standards provided in the kit.
For statistical analysis, samples with cyto/chemokine
levels below or above the detection limits were arbitrar-
ily assigned the values corresponding to the minimum
(3.2 pg/ml) or maximum (10,000 pg/ml) limits respect-
ively, spanning the dynamic range of the assay, and fol-
lowing the manufacturer’s instructions.
Data sources
Peer-reviewed articles were searched using the Medical
Literature Analysisand Retrieval System Online (National
Library of Medicine, Bethesda, Maryland) and Web
of Science (Thomson Reuters, New York, NY) until
December of 2010, using the key words Bacterial
Meningitis plus cytokine plus patient. Additionally,
words such as interferon, interleukin, IL-1β, IL-2, IL-6,
TNF-α, IFN-γ, IL-10, IL-1Ra, CXCL8/IL-8, CCL2/MCP-1,
CCL3/MIP-1α, CCL4/MIP-1β and G-CSF were indentified
in the retrieved articles, and reference lists of relevant
studies were searched for any additional information.
Study selection and data extraction
Original studies measuring cyto/chemokine concentra-
tions in the CSF of living subjects diagnosed with PM
and MM were included. The inclusion criteria required
was the presence of the pathogen in the CSF culture or
antigen agglutination tests on CSF. Studies measuring
cyto/chemokine concentrations from CSF following
stimulation and other diseases which can disturb the
immune response were excluded to avoid bias associ-
ated with the immune challenge. The results of each
relevant article were critically analyzed and data of
mean, median, standard deviation (SD), standard error
(SE), confidence interval (CI) and percentage of each
cyto/chemokine concentration for PM and MM were
extracted. Studies with qualitative results such as western
blot or protein array test were not included.
Statistical analysis
Data were analyzed using Prism 5.0 (GraphPad, San Diego,
CA, USA) and tested for normality using Kolmogorov-
Smirnov normality test. Almost all the variables did not fit
to normal distribution and were analyzed with non-parametric methods. Differences between groups were
analyzed using the one-way ANOVA non-parametric
Kruskal-Wallis test. Data are expressed as median and (25;
75 percentiles). Pair-wise analysis between two groups was
performed using the Mann Whitney test. For all the statis-
tical tests, values of P < 0.05 were considered significant.
Results
CSF samples and cyto/chemokine measurement
In our work, S. pneumoniae was diagnosed in sixteen
patients and N. meningitidis in twelve. At the time of
diagnosis 5 patients with PM reported that had been sick
for 12–48 hours, and 11 had been sick for >2 days.
Fever, headache, neck stiffness were present in all pa-
tients during clinical diagnosis. PM was associated with
brain abscess (n = 3), CSF fistula (n = 2) and acute otitis
media (n = 1). Out of 16 patients with PM, 2 died and 14
were cured after standard therapy. Four patients with
MM had been sick for <12 hours, 1 had been sick for
12–48 hours, and 7 had been sick for >2 days. As ob-
served for PM, almost all patients with MM presented
fever, headache, neck stiffness, mental confusion and
petechias. In some cases, MM was associated with
meningococcemia (n = 4). All patients with MM in-
cluded in this study were cured. Overall, the majority
of patients in the study were adult. Only six patients
under 18 years old were included in PM and four in MM
groups. CSF biochemical parameters of each causative
agent, including the number of leucocytes, protein, and
glucose content results, are presented in Table 1.
The comparison of the concentration of cyto/
chemokines in CSF samples is shown in Figure 1. Signifi-
cant differences in the levels of cyto/chemokines between
PM and MM groups were not observed, except for IFN-γ.
Elevated level of IFN-γ was observed in the patients
with PM (median 237.2 pg/mL, range 34.5-624.7 pg/mL;
P < 0.05 ) compared to MM (median 10.33 pg/mL, range
3.5-41.1 pg/mL). Although not statistically significant,
an increased level of IL-2 was also observed in pa-
tients with PM (median 3.2 pg/mL, range 3.2-22.8 pg/mL;
P = 0.08) compared to MM (median 3.2 pg/mL, range 3.2-
3.2 pg/mL). Other immune modulators, not identified or
poorly identified in prior reports, such as IL-10, IL-1Ra,
CCL4/MIP-1β e G-CSF, were measured and no significant
difference was observed between the pathogens.
Comparative analyses of cytokines levels considering
the time of symptoms prior to LP were done. Patients
with LP performed within 48 hours (<48 hours) from
the initial symptoms were compared to the patients with
LP performed more than 48 h after (>48 h) of the onset
of symptoms. Firstly, patients with PM or MM were
compared separately. Among patients with PM, elevated
levels (P <0.05) of IL-1β, MIP-1β and G-CSF were ob-
served in group <48 h, while the patients with MM of
Table 1 Categorization of the meningitis etiologies according CSF routine investigation
CSF (n samples)
Agea Cell counta Proteinb Glucosea
(years) (cells/mm3) (g/l) (mg/dl)
S. pneumoniae (16) 30 (5; 53) 733 (396; 2,520) 211.6 ± 51.45 17.5 (5; 57)
N. meningitidis (12) 23 (7; 27) 3,360 (929; 12,925)c 150.4 ± 29.8 44.5 (5; 60)
aValues are represented as median (25; 75 percentiles); bValues are represented as mean ± SE; cSignificant value compared to S. pneumoniae (P ≤ 0.05).
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TNF-α, IL-10, MIP-1α, MIP-1β, G-CSF, in comparison
with patients of group >48 h (data not shown). Further,
the comparative analyses in relation to the time of LP
was done between PM and MM patients. Concerning
the time <48 h, higher levels of IFN-γ were observed in
patients with PM (median 521.7 pg/mL, range 311.2-
1353 pg/mL; P < 0.01 ) compared to MM (median
33.45 pg/mL, range 7.4-92.6 pg/mL), while TNF-α was
significantly higher in the CSF of patients with MM (me-
dian 2549 pg/mL, range 1047–6513 pg/mL; P < 0.05)
compared to patients with PM (median 340.4 pg/mL,
range 241.5-895.5 pg/mL) (Figure 2). Between the group
>48 h, PM patients showed significant higher levels of
IFN-γ, TNF-α, MIP-1α and MIP-1β compared to MM
patients (Figure 3). In addition, cytokine levels were
compared according to the age of the patients but sig-
nificant differences were not observed between children
(<18 years old) and adults (>18 years old).Figure 1 Comparison of cyto/chemokines levels in CSF from S. pneum
similar levels of cyto/chemokines compared to N. meningitidis patients, exc
number of samples due to CSF availability. Dotted lines mark the upper anRatio between cyto/chemokine concentration and
number of cell in CSF (strength of cyto/chemokine release
index)
Cyto/chemokine concentrations were individually cat-
egorized by the number of cells in CSF to determine
a cyto/chemokine release index. This index was indir-
ectly used to compare the strength of activation of
the immune response and the release of cyto/chemo-
kine promoted for each pathogen. In order to avoid
the interference of cyto/chemokines originated from
the blood as result of the BBB permeability, CSF
cyto/chemokine levels were firstly divided through the
CSF protein level and then divided by the number of
cells to correct the BBB disturbance. The data dem-
onstrated a higher cyto/chemokine/cell number ratio
during PM (Figure 4). As observed, PM is character-
ized by a significant release of chemokines, growth
factors and anti inflammatory cytokines. Significant P
values are shown in the Figure 4.oniae and N. meningitidis patients. S. pneumoniae patients showed
ept for IFN-γ (P < 0.05 by Mann Whitney test). IL-8 shows a lower
d lower limits of detection.
Figure 2 Levels of IFN-γ and TNF-α in the CSF of patients with LP within 48 h (<48 h) from initial symptoms. S. pneumoniae patients
showed higher levels of IFN-γ compared to N. meningitidis patients (P < 0.01 by Mann Whitney test). The level of TNF-α in the patients with MM
was significantly higher than patients with PM (P < 0.05 by Mann Whitney test). Dotted lines mark the upper and lower limits of detection.
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concentration
A total of 282 records of cyto/chemokine studies during
BM were retrieved from the literature search. Out of
282, only 7 were included in the search criteria of this
study (Table 2). Notably, selected reports showed the
concentration of TNF-α comprises 6/7 studies, following
IL-6, IL-1β and IFN-γ with 2/7 studies, and only 1/7 of
the retrieved reports measured the concentration of
IL-10, IL-1Ra, CXCL8/IL-8, CCL2/MCP-1 and CCL3/
MIP-1α. Reports showing the concentration of IL-2,
IL-1Ra, CCL4/MIP-1β and G-CSF in CSF of human
patients during PM or MM were not observed in this
literature screening. TNF-α howed a contradictory re-
sult in the different studies, 2/6 of them demon-
strated elevated levels of TNF-α during meningitis
caused by S. pneumoniae, while 4/6 demonstrated theFigure 3 Comparison of cytokine levels in patients with LP performed
showed higher levels of IFN-γ, TNF-α, MIP-1α e MIP-1β compared to N. me
the upper and lower limits of detection.highest levels during NM [17,21-26]. In the two reports
that IFN-γ was measured, the values were significantly
higher in meningitis caused by S. pneumoniae than by
N. meningitides [23,25]. Mastroianni et al. [17] observed
similar levels of CXCL8/IL-8 and CCL3/MIP-1α in
meningitis caused by both studied pathogens, although
CCL2/MCP-1 was higher in patients with NM. The cyto-
kine IL-6 levels were observed in two studies, but they
were controversial and not conclusive, due to the small
number of patients included in each study [21,24].
Almost all studies showed elevated cyto/chemokine
concentrations in BM patients when compared with
healthy subjects. The works included a variety of pa-
tients of different ages, 4/7 studies showed cytokines
levels in infants, children and adolescents [21,23-25],
while 2/7 included only adult patients [22,26] and 1/7
studies included both children and adults [17]. Theafter 48 h (>48 h) from initial symptoms. S. pneumoniae patients
ningitidis patients (P < 0.05 by Mann Whitney test). Dotted lines mark
Figure 4 Ratio between cyto/chemokines and the number of PMN cells during infection. Each value of cyto/chemokine was individually
divided per amount of cells. During pneumococcal meningitis (●) cells demonstrated higher ability to release cyto/chemokines than
meningococcal meningitis (○). IL-8 shows a lower number of samples due to CSF availability.
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in 4 of 7 studies the range was 1 to 12 individuals for
both pathogens [17,23,26], while 3/7 had from 19 to 28
individual for both pathogens [17,18,21]. Only one study
described the presence of neurological sequelae, includ-
ing hearing loss and cerebral atrophy, relating to the
pathogen [25]. Data of IL-1β, IL-6, TNF-α, IFN-γ, IL-10,
CXCL8/IL-8, CCL2/MCP-1 and CCL3/MIP-1α concen-
trations were measured from CSF patients using only two
types of techniques, ELISA (5/7) and immunoradiometric
assays (2/7).
Discussion
Different experimental approaches have been used to
analyze the expression levels of the immune modulators,
such as microarray and ELISA assays. In general, studiesTable 2 Comparative literature screening of cytokine measure
meningitis patients
IL-1β TNF-α IL-6 IFN -γ
S.p N.m. S.p. N.m. S.p. N.m. S.p. N.m.
2988
(3)
268
(3)
4238
(3)
57
(3)
2.5 (u/ml)
(3)
<0.1 (u/ml)
(3)
320
(10)
300
(18)
450
(10)
500
(18)
584
(14)
2827
(7)
2324
(6)
414
(13)
100%
(6)
46%
(13)
140
(2)
2007
(1)
8225
(4)
4500
(1)
23.69
(2)
86
(4)
9.36
(2)
44.8
(4)
S.p. Streptococcus pneumonia, N.m. Neisseria meningitides, Values without units are inhave mainly focused on the comparison of BM and men-
ingitis caused by other infectious agents such as viruses
and fungi, using healthy individuals as control [27,28].
However, the comparative analysis in relation to the
levels of cytokines expressed during PM and MM has
been little explored. The literature screening revealed
the need of more comparative studies, in particular for
cyto/chemokines poorly studied in BM patients, such as
IL-10, CXCL8/IL-8, CCL3/MIP-1α and CCL2/MCP-1.
To our knowledge, our work is the first to assess the
levels of cytokines IL-2, IL-1Ra, CCL4/MIP-1β and G-CSF
in patients with PM and MM. In contrast, some cytokines
have been well characterized in BM such as IL-1β, TNF-α
and IL-6, which have received more attention in the
majority of the studies. In general, a limited profile of
cytokine expression from the two major meningitis-ments in CSF from pneumococcal and meningococcal
IL-10 MIP-1α MCP-1 IL-8 References
S.p. N.m. S.p. N.m. S.p. N.m. S.p. N.m.
[25]
[26]
[22]
736
(6)
654
(13)
[23]
[21]
[24]
23
(7)
25
(5)
3145
(7)
4604
(5)
4454
(7)
4525
(5)
[17]
pg/mL. Parenthesis shows the number of patients included in each study.
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multiplex method in our work allowed the comparison
between patients with PM and MN with a broader
spectrum of cytokines analyzed simultaneously.
In all analyzed studies, including ours, some limita-
tions are observed. Among these, the small number of
patients and a lack of correlation between cytokines
levels and symptoms of the disease and its sequelae after
treatment, which may be related to some aspects of BM.
Collection of CSF is an invasive procedure, therefore
obtaining the samples is usually associated with routine
diagnosis of the disease, which generally only occurs in
emergency situations. In addition, poor hospital condi-
tions in the public health system of developing coun-
tries, where BM cases occur more frequently, make it
difficult access to patients’ clinical data.
TNF-α is one of the most studied cytokine during BM
and has been identified as a useful complementary tool
to improve the diagnosis of meningitis, especially in cases
where the CSF examination is inconclusive. Although this
cytokine seems to be important in driving several mecha-
nisms underlying the immune response, our experimental
data and the literature screening showed that this cytokine
is not differentially expressed during meningitis caused by
S. pneumoniae or N. meningitidis [22,24,27]. However, in
relation to the time of LP, in the group <48 h we observed
that the TNF-α levels are significantly elevated in CSF of
patients with MM, but the same result is not repeated
when LP was performed after 48 h from onset of symp-
toms. This data suggest a rapid decline of TNF-α during
MM. This observation is in agreement with previous
works. Van Deuren et al. [29] analyzed the kinetics of the
TNF-α release in the animal models of meningococcal
disease and sepsis and observed that TNF-a reached the
maximal level in 1–2 h after LPS injection, becoming
undetectable after 18–24 h. In human patients, the highest
level of TNF-α can be detectable in the first 48 h of
disease onset, decreasing after this period, which suggest
that after a proinflammatory state, a down regulation of
TNF-α production may represent a transition to an anti‐
inflammatory state as a protective mechanism [30-32].
The IL-6 levels are also elevated during BM and some
researchers have tried to associate this with TNF-α for
the differential diagnosis of BM, but without success
until now. Dulkerian et al. [21] and Mukai et al. [24] ob-
served high levels of IL-6 during BM without differences
between PM and MM. Other cytokines or chemokines,
such as IL-1β, IL-10, CXCL8/IL-8, CCL3/MIP-1α and
CCL2/MCP-1 did not demonstrate any significant differ-
ence between pathogens [17,23,26,27]. Corroborating
with these authors, our measurements also did not show
differences between pathogens for these cytokines.
It is plausible that additional factors can lead to differ-
ences in the cytokine expression, such as the type of thepathogen strain, the host’s age and the time of the LP
after infection (as it was observed in our data). Strains of
N. meningitidis seem to be able to induce different cyto-
kine profiles [33,34]. Considering the age of the patients,
Sharief et al. [26] observed that concentrations of TNF-
α and IL-1β in CSF of patients with bacterial meningitis
were not age-dependent. Additionally, Dulkerian et al.
[21] demonstrates that neonates and young infants re-
spond to pathogen invasion with the release of cytokines
at comparable levels to those found in older children
and adolescents. Similarly in our study, age-related dif-
ferences were not observed (data not shown). However,
in relation to the time of LP, we observed some differ-
ences between the pathogens. The MM patients seem to
have a decay of cytokine (such as TNF-α, IL-1β, IL-10,
MIP-1α, MIP-1β and G-CSF) levels faster than patients
with PM, since decreased levels of certain cytokines were
observed in the group >48 h.
IFN-γ was the unique protein that showed higher
concentration in patients with PM compared with
MM independent of the time of the LP. Kornelisse et al.
[23] observed that IFN-γ was significantly higher in
patients with PM than in children with meningitis caused
by H. influenza or N. meningitidis and obtained data
suggesting that the production of IFN-γ in the CSF from
patients with bacterial meningitis is induced by IL-12, with
TNF-α as a co-stimulator. The high IFN-γ production in
monocytes culture seems to be mainly attributed to
Gram-positive bacteria, which induce much more IL-12
than Gram-negative bacteria [35].
IFN-γ is involved in the stimulation of non-specific
defense mechanisms of macrophages and polymorpho-
nuclear leukocytes, such as phagocytosis and secretion of
reactive oxygen intermediates [36]. Furthermore, our data
also showed that IL-2 seems to be more pronounced in
PM than in MM. The highest expression of IFN-γ and
IL-2 during PM suggests the occurrence of a Th1 im-
mune response [37]. In fact, TH1 and TH17 response
were observed in a co-culture model of human monocytes
and CD4+T cells stimulated with S. pneumoniae [38].
The difference in the degree of immune response ob-
served during pneumococcal infection may be related to
the best or worst outcome of the disease [39]. A deeper
understanding of the immune response pathways against
each pathogen, such as the type of Th response, can help
to develop adjunctive immunotherapy using Th-polarized
cytokines to increase host defense and accelerate healing
of the pathogen.
Patients with PM, even with significantly lower num-
bers of WBC as demonstrated in Table 1, possess cyto/
chemokines concentration at the same levels of patients
with MM. Normalized concentrations of inflammatory
mediators by cell count suggest a higher degree of acti-
vation on a cellular level, mainly during meningitis
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the IFN-γ concentration can be reflected in the potential
of cells to release inflammatory cytokines, or this medi-
ator can work as a signal to regulate invading leukocytes
during BM [40].
The high immunogenicity of S. pneumoniae caused by
cell components, e.g., pneumolysin, lipoteichoic acid and
nucleic acids, can be responsible to release an elevated
amount of cytokines per cell number [41,42]. Moreover,
anti-inflammatory cytokines such as, IL-1Ra and IL-10
demonstrated the highest values to this index of cell
activation. These inflammatory modulators could be
blocking the recruitment of other cells. Although IL-8
and MCP-1 are important to attract phagocytic cells
and have been detected at similar levels in both path-
ogens, the number of cells was significantly higher
during MM than PM. Some studies have shown that
IL-8 from human and rabbits is not able to induce
pleocytosis [43,44]. In addition, pleocytosis has not
been shown to be directly correlated to a specific
chemokine, but can be correlated to the shift of the
type of invading leukocyte [17,40,45]. No correlation
between the chemokines IL-8, MCP-1 and MIP-1α
levels and the total number of leucocytes in the CSF
during BM was found. Even when separately compar-
ing either CSF concentrations of IL-8 with neutrophil
counts, or MCP-1 and MIP-1α with mononuclear cells in
the CSF, no correlation was observed [17].
Even though the amount of cytokines and chemokines by
cell counts differ between pathogens, the overall profile of
these mediators in the CNS seems to be very similar. How-
ever, based on the IFN-γ, TNF-α and IL-2 found in this
study, S. pneumoniae can trigger a Th1 response, differing
from N. meningitidis in this aspect, which needs to be bet-
ter investigated. This information about T helper response
may also facilitate the design of meningitis vaccines based
on cell-mediated immunity and provide new approaches
based on the susceptibility of each patient to the disease.
BM outcome is correlated with severity of the inflam-
matory response in the subarachnoid space, thus, it is
clear the importance of steroid therapy during BM.
However, the benefit of adjunctive dexamethasone for all
or any subgroup of patients with bacterial meningitis re-
mains unproven [20,46]. Considering the data on cyto-
kine levels, no changes in the regimen of dexamethasone
for PM or MM would be need. However, different path-
ogens seem trigger a heterogeinity of type and degree of
immune response, thus, advances in the pathogen-
specific anti-inflammatory therapy are needed in order
to better prognosis for BM patients.
Conclusions
In this work, the basic knowledge of the expression of sev-
eral cyto/chemokines during PM and MM was increased.The modulation of cytokine levels in meningitis of diverse
bacterial etiologies may be a useful strategy to improve
the outcome in terms of morbidity and mortality. How-
ever, other inflammatory proteins that could play import-
ant roles in the steps of immune response were not
included in the present study. In the future, more system-
atic studies containing a greater number of individuals,
expanding ranges of cytokines and associating with time,
sequels and the outcome of meningitis disease should be
done to contribute to a more detailed understanding of
the pathogenesis underlying meningitis.
Abbreviations
BM: Bacterial meningitis; CSF: Cerebrospinal fluid; PM: Pneumococcal
meningitis; MM: Meningococcal meningitis; WBC: White blood cell count;
LP: Lumbar puncture; CNS: Central nervous system; PMN: Polymorphonuclear
granulocytes; IL: Interleukin; CXCL: Chemokine (c-x-c motif) Ligand;
MCP: Monocyte Chemotactic Protein; CCL: Chemokine (C-C motif) Ligand;
MIP: Macrophage Inflammatory Protein; TNF-α: Tumour Necrosis Factor-alpha;
IFN-γ: Interferon-gamma; G-CSF: Granulocyte Colony-Stimulating Factor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LC performed the experiments, analyzed the data, and drafted the
manuscript. DG aided in performing the experiments. SL designed the study
and revised the manuscript. LA designed the study, analyzed the data, and
revised the manuscript. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by UBS Optimus Foundation and CNPq. We would
like to thank the team of Hospital Giselda Trigueiro for their help with the
sample collected. The authors LGC and LFAL are grateful to CNPq (Brazil) for
the fellowships.
Author details
1Departamento de Biologia Celular e Genética, Centro de Biociências,
Universidade Federal do Rio Grande do Norte, Campus Universitário, Lagoa
Nova, Natal, RN 59078-970, Brazil. 2Institute for Infectious Diseases, University
of Bern, Friedbuehlstrasse 51, Bern CH-3010, Switzerland.
Received: 8 August 2012 Accepted: 9 July 2013
Published: 17 July 2013
References
1. Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, Reingold AL,
Lefkowitz L, Perkins BA: Bacterial meningitis in the United States in 1995.
N Engl J Med 1997, 337:970–9762.
2. Silva WA, Pinheiro AM, Coutinho LG, Marinho LA, Lima LF: Epidemiological
profile of acute bacterial meningitis in the state of Rio Grande do Norte,
Brazil. Rev Soc Bras Med Trop 2010, 43:455–457.
3. Novaes HM, Sartori AM, Soárez PC: Hospitalization rates for pneumococcal
disease in Brazil, 2004–2006. Rev Saude Publica 2011, 45:539–547.
4. Sáfadi MA, Cintra OA: Epidemiology of meningococcal disease in Latin
America, current situation and opportunities for prevention. Neurol Res
2010, 32:263–271.
5. Tauber MG, Moser B: Cytokines and chemokines in meningeal inflammation,
biology and clinical implications. Clin Infect Dis 1999, 28:1–11.
6. van Furth AM, Roord JJ, van Furth R: Roles of proinflammatory and anti-
inflammatory cytokines in pathophysiology of bacterial meningitis and
effect of adjunctive therapy. InfectImmun 1996, 64:4883–4890.
7. Brandt CT, Caye-Thomasen P, Lund SP, Worsoe L, Ostergaard C, Frimodt-
Moller N, Espersen F, Thomsen J, Lundgren JD: Hearing loss and cochlear
damage in experimental pneumococcal meningitis, with special
reference to the role of neutrophil granulocytes. Neurobiol Dis 2006,
23:300–311.
Coutinho et al. BMC Infectious Diseases 2013, 13:326 Page 9 of 9
http://www.biomedcentral.com/1471-2334/13/3268. Haberl RL, Anneser F, Kodel U, Pfister HW: Is nitric oxide involved as a
mediator of cerebrovascular changes in the early phase of experimental
pneumococcal meningitis? NeurolRes 1994, 16:108–112.
9. Leppert D, Leib SL, Grygar C, Miller KM, Schaad UB, Hollander GA: Matrix
metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during
bacterial meningitis, association with blood–brain barrier damage and
neurological sequelae. ClinInfect Dis 2000, 31:80–84.
10. Zwijnenburg PJ, de Bie HM, Roord JJ, van der Poll T, van Furth AM:
Chemotactic activity of CXCL5 in cerebrospinal fluid of children with
bacterial meningitis. J Neuroimmunol 2003, 145:148–153.
11. Azuma H, Tsuda N, Sasaki K, Okuno A: Clinical significance of cytokine
measurement for detection of meningitis. J Pediatr 1997, 131:463–465.
12. Klein M, Obermaier B, Angele B, Pfister HW, Wagner H, Koedel U, Kirschning
CJ: Innate immunity to pneumococcal infection of the central nervous
system depends on toll-like receptor (TLR) 2 and TLR4. J Infect Dis 2008,
198:1028–1036.
13. Mogensen TH, Paludan SR, Kilian M, Ostergaard L: Live Streptococcus
pneumoniae, Haemophilus influenzae, and Neisseria meningitidis activate
the inflammatory response through Toll-like receptors 2, 4, and 9 in
species-specific patterns. J Leukocyte Biol 2006, 80:267–277.
14. Ribes S, Ebert S, Regen T, Agarwal A, Tauber SC, Czesnik D, Spreer A,
Bunkowski S, Eiffert H, Hanisch UK, Hammerschmidt S, Nau R: Toll-like
receptor stimulation enhances phagocytosis and intracellular killing of
nonencapsulated and encapsulated Streptococcus pneumoniae by
murine microglia. Infect Immun 2010, 78:865–871.
15. Sjolinder H, Mogensen TH, Kilian M, Jonsson AB, Paludan SR: Important role
for Toll-like receptor 9 in host defense against meningococcal sepsis.
InfectImmun 2008, 76:5421–5428.
16. Kastenbauer S, Koedel U, Becker BF, Pfister HW: Oxidative stress in bacterial
meningitis in humans. Neurology 2002, 58:186–191.
17. Mastroianni CM, Lancella L, Mengoni F, Lichtner M, Santopadre P,
D’Agostino C, Ticca F, Vullo V: Chemokine profiles in the cerebrospinal
fluid (CSF) during the course of pyogenic and tuberculous meningitis.
Clin Exp Immunol 1998, 114:210–214.
18. de Jonge RC, van Furth AM, Wassenaar M, Gemke RJ, Terwee CB: Predicting
sequelae and death after bacterial meningitis in childhood, a systematic
review of prognostic studies. BMC Infect Dis 2010, 10:232.
19. Worsøe L, Cayé-Thomasen P, Brandt CT, Thomsen J, Østergaard C: Factors
associated with the occurrence of hearing loss after pneumococcal
meningitis. Clin Infect Dis 2010, 51:917–924.
20. Borchorst S, Møller K: The role of dexamethasone in the treatment of
bacterial meningitis - a systematic review. Acta Anaesthesiol Scand 2012,
56:1210-1221.
21. Dulkerian SJ, Kilpatrick L, Costarino AT Jr, McCawley L, Fein J, Corcoran L,
Zirin S, Harris MC: Cytokine elevations in infants with bacterial and
aseptic meningitis. J Pediatr 1995, 126:872–876.
22. Glimaker M, Kragsbjerg P, Forsgren M, Olcen P: Tumor necrosis factor-
alpha (TNF alpha) in cerebrospinal fluid from patients with meningitis of
different etiologies, high levels of TNF alpha indicate bacterial
meningitis. J Infect Dis 1993, 167:882–889.
23. Kornelisse RF, Hack CE, Savelkoul HF, van der Pouw Kraan TC, Hop WC, van
Mierlo G, Suur MH, Neijens HJ, de Groot R: Intrathecal production of
interleukin-12 and gamma interferon in patients with bacterial
meningitis. Infect Immun 1997, 65:877–881.
24. Mukai AO, Krebs VL, Bertoli CJ, Okay TS: TNF-alpha and IL-6 in the
diagnosis of bacterial and aseptic meningitis in children. Pediatr Neurol
2006, 34:25–29.
25. Ohga S, Aoki T, Okada K, Akeda H, Fujioka K, Ohshima A, Mori T,
Minamishima I, Ueda K: Cerebrospinal fluid concentrations of interleukin-
1 beta, tumour necrosis factor-alpha, and interferon gamma in bacterial
meningitis. Arch Dis Child 1994, 70:123–125.
26. Sharief MK, Ciardi M, Thompson EJ: Blood–brain barrier damage in
patients with bacterial meningitis, association with tumor necrosis
factor-alpha but not interleukin-1 beta. J Infect Dis 1992, 166:350–358.
27. Akalin H, Akdis AC, Mistik R, Helvaci S, Kilicturgay K: Cerebrospinal fluid
interleukin-1 beta/interleukin-1 receptor antagonist balance and tumor
necrosis factor-alpha concentrations in tuberculous, viral and acute
bacterial meningitis. Scand J Infect Dis 1994, 26:667–674.
28. Friedland JS, Shattock R, Remick DG, Griffin GE: Mycobacterial 65-kD heat
shock protein induces release of proinflammatory cytokines from human
monocytic cells. Clin Exp Immunol 1993, 91:58–62.29. van Deuren M, Netea MG, Hijmans A, Demacker PN, Neeleman C, Sauerwein
RW, Bartelink AK, van der Meer JW: Posttranscriptional down-regulation of
tumour necrosis factor-alpha and interleukin-1beta production in acute
meningococcal infections. J Infect Dis 1998, 177:1401–1405.
30. Marzouk O: Clinical and laboratory aspects of meningococcal disease in
childhood. MD Thesis: Liverpool University; 1994.
31. van Deuren M, van der Ven-Jongekrijg J, Demacker PN, Bartelink AK, van
Dalen R, Sauerwein RW, Gallati H, Vannice JL, van der Meer JW: Differential
expression of proinflammatory cytokines and their inhibitors during the
course of meningococcal infections. J Infect Dis 1994, 169:157–161.
32. Baines PB, Hart CA: Severe meningococcal disease in childhood. Br J
Anaesth 2003, 90:72–83.
33. Davenport V, Groves E, Hobbs CG, Williams NA, Heyderman RS: Regulation
of Th-1 T cell-dominated immunity to Neisseria meningitidis within the
human mucosa. Cell Microbiol 2007, 9:1050–1061.
34. Holub M, Scheinostova M, Dzupova O, Fiserova A, Beran O, Kalmusova J,
Musilek M, Krizova P: Neisseria meningitidis strains from patients with
invasive meningococcal disease differ in stimulation of cytokine
production. Folia Microbiol 2007, 52:525–528.
35. Hessle C, Andersson B, WoldA E: Gram-positive bacteria are potent
inducers of monocytic interleukin-12 (IL-12) while gram-negative
bacteria preferentially stimulate IL-10 production. Infect Immun 2000,
68:3581–3586.
36. Borish LC, Steinke JW: 2. Cytokines and chemokines. J Allerg ClinImmun
2003, 111:S460–S475.
37. D’Elios MM, Benagiano M, Della Bella C, Amedei A: T-cell response to
bacterial agents. J Infect Dev C tries 2011, 5:640–645.
38. Olliver M, Hiew J, Mellroth P, Henriques-Normark B, Bergman P: Human
monocytes promote Th1 and Th17 responses to Streptococcus
pneumoniae. Infect Immun 2011, 79:4210–4217.
39. Fortnum HM: Hearing impairment after bacterial meningitis, a review.
Arch Dis Child 1992, 67:1128–1133.
40. Hausler KG, Prinz M, Nolte C, Weber JR, Schumann RR, Kettenmann H,
Hanisch UK: Interferon-gamma differentially modulates the release of
cytokines and chemokines in lipopolysaccharide- and pneumococcal cell
wall-stimulated mouse microglia and macrophages. Eur J Neurosc 2002,
16:2113–2122.
41. Deshmukh SD, Kremer B, Freudenberg M, Bauer S, Golenbock DT, Henneke
P: Macrophages recognize streptococci through bacterial single-stranded
RNA. EMBO Rep 2010, 12:71–76.
42. Carrol ED, Guiver M, Nkhoma S, Mankhambo LA, Marsh J, Balmer P, Banda
DL, Jeffers G, White SA, Molyneux EM, Molyneux ME, Smyth RL, Hart CA:
High pneumococcal DNA loads are associated with mortality in
Malawian children with invasive pneumococcal disease. Pediatr Infect Dis
J 2007, 26:416–422.
43. Dumont RA, Car BD, Voitenok NN, Junker U, Moser B, Zak O, O’Reilly T:
Systemic neutralization of interleukin-8 markedly reduces neutrophilic
pleocytosis during experimental lipopolysaccharide-induced meningitis
in rabbits. Infect Immun 2000, 68:5756–5763.
44. Ostergaard C, Yieng-Kow RV, Larsen CG, Mukaida N, Matsushima K, Benfield T,
Frimodt-Moller N, Espersen F, Kharazmi A, Lundgren JD: Treatment with a
monocolonal antibody to IL-8 attenuates the pleocytosis in experimental
pneumococcal meningitis in rabbits when given intravenously, but not
intracisternally. Clin Exp Immunol 2000, 122:207–211.
45. Diab A, Abdalla H, Li HL, Shi FD, Zhu J, Hojberg B, Lindquist L, Wretlind B,
Bakhiet M, Link H: Neutralization of macrophage inflammatory protein 2
(MIP-2) and MIP-1alpha attenuates neutrophil recruitment in the central
nervous system during experimental bacterial meningitis. Infect Immun
1999, 67:2590–2601.
46. van de Beek D, Farrar JJ, de Gans J, Mai NT, Molyneux EM, Peltola H, Peto
TE, Roine I, Scarborough M, Schultsz C, Thwaites GE, Tuan PQ, Zwinderman
AH: Adjunctive dexamethasone in bacterial meningitis, a meta-analysis
of individual patient data. Lancet Neurol 2010, 9:254–263.
doi:10.1186/1471-2334-13-326
Cite this article as: Coutinho et al.: Cerebrospinal-fluid cytokine and
chemokine profile in patients with pneumococcal and meningococcal
meningitis. BMC Infectious Diseases 2013 13:326.
